Gutierrez-Valencia, AliciaBenmarzouk-Hidalgo, Omar JLlaves, SilviaFernandez-Magdaleno, TamaraEspinosa, NuriaViciana, PompeyoLopez-Cortes, Luis F2023-01-252023-01-252017http://hdl.handle.net/10668/10699To evaluate if there are significant drug-drug interactions between cobicistat-boosted elvitegravir and 800 mg darunavir once daily taken simultaneously, as has been suggested previously. The study population consisted of three groups of unselected volunteers taking a regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (150, 150, 200 and 300 mg, respectively) co-formulated in a single tablet plus 800 mg darunavir (group A); only co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (group B); and cobicistat-boosted darunavir (800 mg darunavir + 150 mg cobicistat) plus two nucleos(t)ide analogues (group C). Elvitegravir, cobicistat and darunavir concentrations at the end of the dosing interval ( C 24 ) were quantified using a validated LC with tandem MS method. A total of 170 samples were obtained from 24, 32 and 32 patients in groups A, B and C, respectively. In group A, the elvitegravir C 24 were similar to those in group B (233.67 versus 250.39 ng/mL) ( P  =   0.406) and the darunavir C 24 were similar to those in group C (1293.54 versus 1319.34 ng/mL) ( P  =   0.908). The cobicistat C 24 were comparable in groups A and B (20.2 versus 20.9 ng/mL) and slightly higher in group C (27.7 ng/mL) ( P  =   0.059). The results provide evidence of similar elvitegravir and darunavir C 24 concentrations when these drugs are co-administered as co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate plus 800 mg darunavir or dosed separately.enAdultAgedAged, 80 and overAnti-HIV AgentsCobicistatDarunavirDrug CombinationsDrug InteractionsFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedQuinolonesYoung Adultresearch article27999051open access10.1093/jac/dkw4871460-2091https://academic.oup.com/jac/article-pdf/72/3/816/10491287/dkw487.pdf